Capstone Investment Advisors, LLC Corvus Pharmaceuticals, Inc. Transaction History
Capstone Investment Advisors, LLC
- $35.4 Billion
- Q1 2025
A detailed history of Capstone Investment Advisors, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Capstone Investment Advisors, LLC holds 12,644 shares of CRVS stock, worth $52,346. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,644Holding current value
$52,346% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CRVS
# of Institutions
110Shares Held
37.2MCall Options Held
1.37MPut Options Held
338K-
Orbimed Advisors LLC San Diego, CA6.94MShares$28.7 Million0.69% of portfolio
-
Samlyn Capital, LLC New York, NY4.07MShares$16.8 Million0.21% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$13.6 Million10.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$11.5 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$11.1 Million0.14% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $193M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...